Everest Medicines Valuation Multiples

Everest Medicines Overview

About Everest Medicines

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.

Founded

2017

HQ

Employees

651

Website

everestmedicines.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $320M

EBITDA: ($24M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Everest Medicines Financials

Everest Medicines reported last 12-month revenue of $320M and negative EBITDA of ($24M).

In the same LTM period, Everest Medicines generated $228M in gross profit, ($24M) in EBITDA losses, and had net loss of ($20M).

Everest Medicines P&L

In the most recent fiscal year, Everest Medicines reported revenue of $104M and EBITDA of ($130M).

Everest Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX

Everest Medicines Stock Performance

Everest Medicines has current market cap of $2B, and enterprise value of $2B.

Everest Medicines' stock price is $5.06.

Everest Medicines Valuation Multiples

Everest Medicines trades at 4.7x EV/Revenue multiple, and (64.2x) EV/EBITDA.

Everest Medicines Financial Valuation Multiples

As of April 19, 2026, Everest Medicines has market cap of $2B and EV of $2B.

Equity research analysts estimate Everest Medicines' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Everest Medicines has a P/E ratio of (90.2x).

Everest Medicines Margins & Growth Rates

Everest Medicines' revenue in the last 12 month grew by 72%.

Everest Medicines' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Everest Medicines' rule of 40 is 110% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Everest Medicines' rule of X is 258% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Everest Medicines Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Everest Medicines M&A Activity

Everest Medicines acquired XXX companies to date.

Last acquisition by Everest Medicines was on XXXXXXXX, XXXXX. Everest Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Everest Medicines Investment Activity

Everest Medicines invested in XXX companies to date.

Everest Medicines made its latest investment on XXXXXXXX, XXXXX. Everest Medicines invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).